Reuters: Regulatory News: GTx says muscle drug fails in late-stage trials

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Get rewarded for sharing Join the Hotspex panel to play a key role in consumer driven innovation. Have a real impact on the products that go to market and earn great rewards! From our sponsors

GTx says muscle drug fails in late-stage trials Aug 19th 2013, 12:27 Mon Aug 19, 2013 8:27am EDT Aug 19 (Reuters) - GTx Inc said its experimental drug to treat muscle wasting in cancer patients was not effective in improving body mass in late-stage trials. A 3-mg dose of the drug, enobosarm, was tested on about 325 patients with non-small cell lung cancer - the most common form of lung cancer. There is no approved cure for cancer-induced muscle wasting which causes decreased physical function, fatigue and weight loss.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions